List of Excipients in Branded Drug BASIC CARE ACID REDUCER 150

Generic Drugs Containing BASIC CARE ACID REDUCER 150

Company	Ingredient	NDC	Excipient
L Perrigo Company	ranitidine	0113-7852	CELLULOSE, MICROCRYSTALLINE
L Perrigo Company	ranitidine	0113-7852	D&C YELLOW NO. 10
L Perrigo Company	ranitidine	0113-7852	FD&C BLUE NO. 2
L Perrigo Company	ranitidine	0113-7852	FD&C RED NO. 40
L Perrigo Company	ranitidine	0113-7852	HYPROMELLOSES

What are the Most Frequently-Used Excipients in BASIC CARE ACID REDUCER 150?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	D&C YELLOW NO. 10
1	FD&C BLUE NO. 2
1	FD&C RED NO. 40
1	HYPROMELLOSES

Excipient Strategy and Commercial Opportunities for BASIC CARE ACID REDUCER 150

Last updated: March 2, 2026

What are the excipient considerations for BASIC CARE ACID REDUCER 150?

BASIC CARE ACID REDUCER 150 contains active ingredients designed to inhibit gastric acid secretion, typically a proton pump inhibitor or H2 blocker. Selecting excipients involves stability, bioavailability, patient tolerability, and manufacturability.

Key excipients and their roles:

• Binders: Microcrystalline cellulose, povidone. These facilitate tablet cohesion.
• Fillers: Lactose monohydrate, calcium carbonate. They provide volume and influence dissolution.
• Disintegrants: Croscarmellose sodium, sodium starch glycolate. They promote tablet breakup.
• Lubricants: Magnesium stearate. They prevent sticking during manufacturing.
• Coatings: Hydroxypropyl methylcellulose (HPMC). They control dissolution rate and improve stability.

Formulation challenges:

• Acidic pH stability may limit use of certain excipients.
• Compatibility with active drug, especially if it is acid-sensitive.
• Need for taste masking or coating if oral suspension or chewable formats are developed.

What are current regulatory and manufacturing considerations?

Regulatory agencies, including FDA and EMA, emphasize excipient safety and consistency. Common excipients like lactose can pose issues for lactose-intolerant patients. Surfactants and film-coating agents must meet biocompatibility standards.

Manufacturers aim for robust supply chains for primary excipients. Differentiation can be achieved via novel excipients that enhance stability, bioavailability, or patient experience.

What commercial opportunities exist within excipient selection?

Opportunities for innovation:

• Improved bioavailability: Using lipid-based or nanoemulsion excipients to enhance absorption.
• Taste masking: Incorporation of flavoring agents and sweeteners for pediatric formulations.
• Extended-release matrices: Utilizing superdisintegrants and controlled-release polymers to optimize dosing.
• Patient-centric formats: Chewables, orodispersibles, or suspensions aligned with excipients that improve mouthfeel and stability.

Market landscape:

• The global gastric acid reducers market reached approximately USD 23 billion in 2021, expected to grow at a compounded annual growth rate (CAGR) of 3.5% through 2028 (Grand View Research, 2022).
• Patent expirations have opened entry points for generics and OTC formulations focused on excipient innovation.
• Rising prevalence of gastrointestinal disorders and OTC demand spurs opportunities for differentiated products.

Key competitors:

• Major pharmaceutical firms invest in excipient optimization for bioavailability and patient compliance.
• Brands like Prilosec, Nexium, and famotidine-based products focus on formulation improvements.

How can companies leverage excipient strategies for competitive advantage?

• Develop formulations with excipients that improve stability in various storage conditions.
• Invest in bioavailability-enhancing excipients, such as lipid nanoparticles.
• Pursue pediatric and geriatric-friendly formulations validated with safe, tolerable excipients.
• Explore novel excipients that reduce manufacturing costs or extend shelf life.

Conclusion

Excipient selection for BASIC CARE ACID REDUCER 150 impacts drug stability, efficacy, patient tolerability, and manufacturing efficiency. Innovation in excipients can drive product differentiation in a growing market. Companies that optimize excipient strategies aligned with regulatory standards and market needs stand to capture a larger share of the acid reducer segment.

Key Takeaways

• Excipient choice influences drug performance, stability, and patient acceptance.
• Market growth and patent expiries create opportunities for formulation innovation.
• Lipid-based and novel excipients can enhance bioavailability.
• Pediatric and OTC formulations demand tolerable, user-friendly excipient profiles.
• Competitive advantage depends on balancing regulatory compliance, cost, and product differentiation.

FAQs

1. What excipients are most common in acid reducer tablets?
   Microcrystalline cellulose, lactose, croscarmellose sodium, magnesium stearate, and HPMC coating agents.

2. How do excipients affect drug stability?
   They influence moisture uptake, pH environment, and interactions that can degrade the active ingredient.

3. Can novel excipients improve bioavailability?
   Yes, lipid-based or nanotechnology excipients can enhance solubility and absorption.

4. What considerations are crucial for pediatric formulations?
   Tolerability, taste masking, and safety profiles of excipients like sweeteners and flavoring agents.

5. Are there regulatory challenges with excipient innovation?
   Yes, novel excipients must demonstrate biocompatibility and undergo regulatory review for safety.

---

References

[1] Grand View Research. (2022). Gastric Acid Reducers Market Analysis. https://www.grandviewresearch.com/industry-analysis/gastric-acid-reducers-market